BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

There are several Ozempic alternatives available today, like Rybelsus, Mounjaro, Wegovy and Zepbound. Other medications may ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

Arrowhead's plozasiran shows promising Phase 3 data for FCS, with potential blockbuster status, but faces competition. Learn ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

After 16 weeks of treatment, those taking a 10 mg daily dose lost 7.1 kg ... Wegovy (semaglutide), while Lilly’s obesity drug ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

and $549 for the 5-mg dose ($137.25 per vial), which the company noted was "in line with the Zepbound savings program for noncovered individuals." (The new direct single-dose prescriptions cannot ...

Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly ...